A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients

[1]  M. Toungouz,et al.  IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. , 2005, Human Immunology.

[2]  M. Toungouz,et al.  Immunostimulatory properties of human dendritic cells generated using IFN-β associated either with IL-3 or GM-CSF , 2005, Cancer Immunology, Immunotherapy.

[3]  M. Goldman,et al.  Mature dendritic cells differentiated in the presence of interferon‐b and interleukin‐3 prime functional antigen‐specific CD8+ T cells , 2005, Clinical and experimental immunology.

[4]  P. Coulie,et al.  Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[6]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.

[7]  J. Fay,et al.  Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells , 2004, The Journal of experimental medicine.

[8]  J. Berzofsky,et al.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer. , 2004, The Journal of clinical investigation.

[9]  F. Belardelli,et al.  Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1 , 2004, The Journal of Immunology.

[10]  P. Martiat,et al.  Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. , 2004, International immunology.

[11]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[12]  E. Hersh,et al.  Clinical applications of dendritic cell vaccination in the treatment of cancer , 2004, Cancer Immunology, Immunotherapy.

[13]  M. Demoitié,et al.  Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus 1 , 2003, The Journal of Immunology.

[14]  P. Coulie,et al.  Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1 , 2003, The Journal of Immunology.

[15]  T. Di Pucchio,et al.  Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-α , 2003, The Journal of experimental medicine.

[16]  R. Kiss,et al.  111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[18]  I. Salmon,et al.  Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. , 2002, Blood.

[19]  T. Di Pucchio,et al.  Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. , 2001, Blood.

[20]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[21]  P. Coulie,et al.  A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Di Pucchio,et al.  Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice , 2000, The Journal of experimental medicine.

[23]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[24]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[25]  F. Brasseur,et al.  A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.

[26]  W. Oyen,et al.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. , 2003, Cancer research.

[27]  American Society for Histocompatibility and Immunogenetics ASHI 27th Annual Meeting , 2001, Immunogenetics.

[28]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.